Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127798121 | 12779812 | 1 | I | 201208 | 20130226 | 20160926 | 20160926 | PER | US-ASTRAZENECA-2013SE36205 | ASTRAZENECA | 862.00 | MON | F | Y | 80.30000 | KG | 20160926 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127798121 | 12779812 | 1 | PS | BYDUREON | EXENATIDE | 1 | Subcutaneous | EXENATIDE LONG ACTING RELEASE | Y | 73068,72930,72927,72924 | 22200 | 2 | MG | /wk | |||||
| 127798121 | 12779812 | 2 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | Y | 72924,72927 | 22200 | 2 | MG | /wk | ||||||
| 127798121 | 12779812 | 3 | SS | BYETTA | EXENATIDE | 1 | Subcutaneous | 0.25 MG/ML10.0UG UNKNOWN | Y | 0 | 10 | UG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | ||||||
| 127798121 | 12779812 | 4 | SS | BYETTA | EXENATIDE | 1 | Subcutaneous | 5.0UG UNKNOWN | Y | 73068 | 0 | 5 | UG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | |||||
| 127798121 | 12779812 | 5 | SS | BYETTA | EXENATIDE | 1 | Subcutaneous | EXENATIDE LONG ACTING RELEASE2.0MG UNKNOWN | Y | 73068 | 0 | 2 | MG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | /wk | ||||
| 127798121 | 12779812 | 6 | C | LEVEMIR | INSULIN DETEMIR | 1 | Subcutaneous | 15 UNITS INJ QHS | 0 | ||||||||||
| 127798121 | 12779812 | 7 | C | LEVEMIR | INSULIN DETEMIR | 1 | Subcutaneous | 11 UNITS INJ QHS | 0 | ||||||||||
| 127798121 | 12779812 | 8 | C | GLUCOVANCE | GLYBURIDEMETFORMIN HYDROCHLORIDE | 1 | Oral | 1.25-250MG TWO TIMES A DAY | 0 | ||||||||||
| 127798121 | 12779812 | 9 | C | GLUCOVANCE | GLYBURIDEMETFORMIN HYDROCHLORIDE | 1 | Oral | 1.25-250MG TWO TIMES A DAY | 0 | ||||||||||
| 127798121 | 12779812 | 10 | C | GLUCOVANCE | GLYBURIDEMETFORMIN HYDROCHLORIDE | 1 | Oral | 1.25-250MG DAILY | 0 | ||||||||||
| 127798121 | 12779812 | 11 | C | GLUCOVANCE | GLYBURIDEMETFORMIN HYDROCHLORIDE | 1 | Oral | 1.25-250MG DAILY | 0 | ||||||||||
| 127798121 | 12779812 | 12 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 500 MG, QD | 0 | 500 | MG | TABLET | QD | ||||||
| 127798121 | 12779812 | 13 | C | TRULICITY | DULAGLUTIDE | 1 | Oral | 500 MG, QD | 0 | 500 | MG | TABLET | QD | ||||||
| 127798121 | 12779812 | 14 | C | VICTOZA | LIRAGLUTIDE | 1 | Oral | 500 MG, QD | 0 | 500 | MG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127798121 | 12779812 | 1 | Type 2 diabetes mellitus |
| 127798121 | 12779812 | 2 | Type 2 diabetes mellitus |
| 127798121 | 12779812 | 3 | Type 2 diabetes mellitus |
| 127798121 | 12779812 | 4 | Type 2 diabetes mellitus |
| 127798121 | 12779812 | 5 | Type 2 diabetes mellitus |
| 127798121 | 12779812 | 6 | Type 2 diabetes mellitus |
| 127798121 | 12779812 | 7 | Type 2 diabetes mellitus |
| 127798121 | 12779812 | 8 | Type 2 diabetes mellitus |
| 127798121 | 12779812 | 9 | Diabetes mellitus |
| 127798121 | 12779812 | 10 | Type 2 diabetes mellitus |
| 127798121 | 12779812 | 11 | Diabetes mellitus |
| 127798121 | 12779812 | 13 | Diabetes mellitus |
| 127798121 | 12779812 | 14 | Diabetes mellitus |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127798121 | 12779812 | Alopecia | |
| 127798121 | 12779812 | Asthenia | |
| 127798121 | 12779812 | Blood glucose decreased | |
| 127798121 | 12779812 | Cough | |
| 127798121 | 12779812 | Decreased appetite | |
| 127798121 | 12779812 | Diarrhoea | |
| 127798121 | 12779812 | Herpes zoster | |
| 127798121 | 12779812 | Injection site haemorrhage | |
| 127798121 | 12779812 | Injection site nodule | |
| 127798121 | 12779812 | Nasopharyngitis | |
| 127798121 | 12779812 | Nausea | |
| 127798121 | 12779812 | Off label use | |
| 127798121 | 12779812 | Stress | |
| 127798121 | 12779812 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127798121 | 12779812 | 1 | 201208 | 0 | ||
| 127798121 | 12779812 | 2 | 20120914 | 0 | ||
| 127798121 | 12779812 | 3 | 2009 | 2009 | 0 | |
| 127798121 | 12779812 | 4 | 20120426 | 0 | ||
| 127798121 | 12779812 | 5 | 201208 | 0 |